Asia Pacific Biopharma Excipients Market Size, Share & Trends Analysis Report By Product (Solubilizers & Surfactants/Emulsifiers, Polyols, Carbohydrates, Specialty Biopharma Excipients), By Country, And Segment Forecasts, 2024

Description

Asia Pacific Biopharma Excipients Market Growth & Trends:

The Asia Pacific biopharma excipient market size is expected to reach USD 1.1 billion in 2030 and is projected to grow at a CAGR of 5.8% from 2024 to 2030. Patent expiry of blockbuster biologics such as Erbitux, Rituxan, Herceptin, Avastin, Aranesp, and Enbrel by 2030 is encouraging investments in biosimilars R&D by biopharma players. Soaring need for novel additives for development of biologics such as those enhancing lyophilization performance to improve stability of biologics is anticipated to boost the demand for excipients.

As per drug sales record of 2016, eight out of ten top-selling drugs are biologics. Upcoming patent expiry of biologics is leading to increased R&D for biosimilar formulations. Biopharma players in the market are adopting price reduction strategies in order to promote their products. This is triggering the need for consideration of pricing strategy among excipient manufacturers.

Presence of challenges in development of a stable form of biotherapeutic is urging manufacturers to develop novel excipients. Processing and storage of biomolecules are complicated as these products undergo degradation after a slight change in environmental conditions. Rising demand for chemicals that are compatible with these biomolecules and serve additional functions such as binding, bulking, and efficient delivery is stimulating the growth of the market. Technological advancements, such as implementation of nanotechnology in the development of novel compounds to enhance drug delivery, are likely to drive the market. For instance, an Australian provider of microencapsulation for drug delivery, Ceramisphere, expanded its operations for production of nanoparticles with extended-release capacity.

Furthermore, Asian countries such as India & China serve as major markets for biogenerics. Key pharmaceutical players in the market are increasing their R&D activities on follow-on-biologic. Biologics R&D is outsourced to CROs in the region as a consequence of cost efficiency provided by them, which is consequently boosting the demand for excipients.

Asia Pacific Biopharma Excipients Market Report Highlights:

Carbohydrates accounted the largest revenue share due to substantial product penetration in the market owing to higher availability of raw materials as well as easy molecular processing characteristics
Japan dominated the market in terms of revenue. However, in terms of sale volume, the Japanese economy was not on the top as a consequence of high product pricing
In February 2014, International Pharmaceutical Excipients Council of India (IPEC) was launched. Leading international pharmaceutical companies are founder members of this council, which includes Dow Chemicals, Lubrizol, BASF, SPI Pharma, Colorcon, Indchem International. It is estimated to assist the government of India in evolving direction, standards, and development of the excipient industry in the country, thus working in favor of the market
In August 2016, China FDA announced to review excipients as a part of new drug application. The former system considered separate review approvals for a drug, its excipient, and its active ingredient.

Product Code: GVR-2-68038-700-1

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Asia Pacific Biopharma Excipient Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Asia Pacific Biopharma Excipient Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Asia Pacific Biopharma Excipient Market: Product Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Asia Pacific Biopharma Excipient Market: Product Movement Analysis, USD Million, 2023 & 2030
4.3. Solubilizers & Surfactants/Emulsifiers
- 4.3.1. Solubilizers & Surfactants/Emulsifiers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Polyols
- 4.4.1. Polyols Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Carbohydrates
- 4.5.1. Carbohydrates Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Specialty Biopharma Excipients/Others
- 4.6.1. Specialty Biopharma Excipients/Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Asia Pacific Biopharma Excipient Market: Regional Estimates & Trend Analysis

5.1. Asia Pacific Biopharma Excipient Market Share, By Region, 2023 & 2030, USD Million
5.2. Asia Pacific
- 5.2.1. Asia Pacific Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.2.2. Japan
  - 5.2.2.1. Japan Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.2.3. China
  - 5.2.3.1. China Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.2.4. India
  - 5.2.4.1. India Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.2.5. Malaysia
  - 5.2.5.1. Malaysia Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.2.6. South Korea
  - 5.2.6.1. South Korea Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.2.7. Philippines
  - 5.2.7.1. Philippines Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.2.8. New Zealand
  - 5.2.8.1. New Zealand Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.2.9. Australia
  - 5.2.9.1. Australia Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.2.10. Singapore
  - 5.2.10.1. Singapore Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.2.11. Indonesia
  - 5.2.11.1. Indonesia Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

6.1. Recent Developments & Impact Analysis by Key Market Participants
6.2. Company Categorization
6.3. Company Heat Map Analysis
6.4. Company Profiles
- 6.4.1. Signet Excipients Pvt. Ltd.
  - 6.4.1.1. Participant's Overview
  - 6.4.1.2. Financial Performance
  - 6.4.1.3. Product Benchmarking
  - 6.4.1.4. Recent Developments/ Strategic Initiatives
- 6.4.2. ABITEC
  - 6.4.2.1. Participant's Overview
  - 6.4.2.2. Financial Performance
  - 6.4.2.3. Product Benchmarking
  - 6.4.2.4. Recent Developments/ Strategic Initiatives
- 6.4.3. Sigachi Industries.
  - 6.4.3.1. Participant's Overview
  - 6.4.3.2. Financial Performance
  - 6.4.3.3. Product Benchmarking
  - 6.4.3.4. Recent Developments/ Strategic Initiatives
- 6.4.4. Roquette Freres
  - 6.4.4.1. Participant's Overview
  - 6.4.4.2. Financial Performance
  - 6.4.4.3. Product Benchmarking
  - 6.4.4.4. Recent Developments/ Strategic Initiatives
- 6.4.5. Colorcon
  - 6.4.5.1. Participant's Overview
  - 6.4.5.2. Financial Performance
  - 6.4.5.3. Product Benchmarking
  - 6.4.5.4. Recent Developments/ Strategic Initiatives
- 6.4.6. Meggle GmbH & Co. KG
  - 6.4.6.1. Participant's Overview
  - 6.4.6.2. Financial Performance
  - 6.4.6.3. Product Benchmarking
  - 6.4.6.4. Recent Developments/ Strategic Initiatives
- 6.4.7. CLARIANT
  - 6.4.7.1. Participant's Overview
  - 6.4.7.2. Financial Performance
  - 6.4.7.3. Product Benchmarking
  - 6.4.7.4. Recent Developments/ Strategic Initiatives
- 6.4.8. DFE Pharma
  - 6.4.8.1. Participant's Overview
  - 6.4.8.2. Financial Performance
  - 6.4.8.3. Product Benchmarking
  - 6.4.8.4. Recent Developments/ Strategic Initiatives
- 6.4.9. SPI Pharma
  - 6.4.9.1. Participant's Overview
  - 6.4.9.2. Financial Performance
  - 6.4.9.3. Product Benchmarking
  - 6.4.9.4. Recent Developments/ Strategic Initiatives
- 6.4.10. IMCD.
  - 6.4.10.1. Participant's Overview
  - 6.4.10.2. Financial Performance
  - 6.4.10.3. Product Benchmarking
  - 6.4.10.4. Recent Developments/ Strategic Initiatives
- 6.4.11. Spectrum Chemical
  - 6.4.11.1. Participant's Overview
  - 6.4.11.2. Financial Performance
  - 6.4.11.3. Product Benchmarking
  - 6.4.11.4. Recent Developments/ Strategic Initiatives
- 6.4.12. Pharmonix
  - 6.4.12.1. Participant's Overview
  - 6.4.12.2. Financial Performance
  - 6.4.12.3. Product Benchmarking
  - 6.4.12.4. Recent Developments/ Strategic Initiatives
- 6.4.13. BASF SE
  - 6.4.13.1. Participant's Overview
  - 6.4.13.2. Financial Performance
  - 6.4.13.3. Product Benchmarking
  - 6.4.13.4. Recent Developments/ Strategic Initiatives

Asia Pacific Biopharma Excipients Market Size, Share & Trends Analysis Report By Product (Solubilizers & Surfactants/Emulsifiers, Polyols, Carbohydrates, Specialty Biopharma Excipients), By Country, And Segment Forecasts, 2024 - 2030